152 related articles for article (PubMed ID: 36840954)
1. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
[No Abstract] [Full Text] [Related]
2. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
[No Abstract] [Full Text] [Related]
3. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
[TBL] [Abstract][Full Text] [Related]
4. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
Margaretos NM; Panzer AD; Lai RC; Sanon M; Michalopoulos E; Redmond AM; Moghadam R; Chambers JD
J Manag Care Spec Pharm; 2021 Sep; 27(9):1221-1229. PubMed ID: 34464213
[No Abstract] [Full Text] [Related]
5. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
Sussman M; Yu JC; Menzin J
Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
[TBL] [Abstract][Full Text] [Related]
6. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
Chambers JD; Margaretos NM; Enright DE; Wang R; Ye X
Pharmacoeconomics; 2022 Feb; 40(2):225-232. PubMed ID: 34697718
[TBL] [Abstract][Full Text] [Related]
7. Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
Levine AA; Panzer AD; Kauf TL; O'Sullivan AK; Strand L; Chambers JD
J Manag Care Spec Pharm; 2023 Jun; 29(6):607-613. PubMed ID: 37276044
[No Abstract] [Full Text] [Related]
8. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
9. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
[No Abstract] [Full Text] [Related]
10. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
[TBL] [Abstract][Full Text] [Related]
11. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
[No Abstract] [Full Text] [Related]
12. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
[No Abstract] [Full Text] [Related]
13. Use of prescriber requirements among US commercial health plans.
Lenahan K; Panzer AD; Gertler R; Chambers JD
J Manag Care Spec Pharm; 2021 Dec; 27(12):1757-1762. PubMed ID: 34818091
[No Abstract] [Full Text] [Related]
14. Underestimating the Value of an Intervention: The Case for Including Productivity in Value Assessments and Formulary Design.
Karmarkar T; Graff JS; Westrich K
J Manag Care Spec Pharm; 2020 May; 26(5):652-661. PubMed ID: 32347177
[TBL] [Abstract][Full Text] [Related]
15. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
[No Abstract] [Full Text] [Related]
16. Characterizing health plan evidence review practices.
Panzer AD; Enright DE; Graff J; Chambers JD
J Manag Care Spec Pharm; 2022 Sep; 28(9):1053-1058. PubMed ID: 36001106
[No Abstract] [Full Text] [Related]
17. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
Yu T; Jin S; Li C; Chambers JD; Hlávka JP
BioDrugs; 2023 Jul; 37(4):531-540. PubMed ID: 37004706
[TBL] [Abstract][Full Text] [Related]
18. Limited role of patient input in specialty drug coverage policies.
D'Cruz B; Graff JS; Panzer AD; Chambers JD
J Manag Care Spec Pharm; 2021 Aug; 27(8):1067-1076. PubMed ID: 34337996
[No Abstract] [Full Text] [Related]
19. What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?
Panzer AD; Margaretos NM; Lai RC; Enright DE; Chambers JD
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1307-1311. PubMed ID: 32212282
[TBL] [Abstract][Full Text] [Related]
20. Variation in US private health plans' coverage of orphan drugs.
Chambers JD; Panzer AD; Kim DD; Margaretos NM; Neumann PJ
Am J Manag Care; 2019 Oct; 25(10):508-512. PubMed ID: 31622066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
